Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Streptococcus cristatus is a Gram-positive, facultative anaerobic bacterium belonging to the Streptococcus mitis group, commonly found in the human oral cavity (Handley et al., 1991). It was formerly known as Streptococcus crista and is characterized by tufts of fimbriae on its surface that aid in biofilm formation and attachment to oral surfaces (Handley et al., 1991; PubMed). While generally considered a commensal organism associated with oral health, it can act as an opportunistic pathogen, particularly in cases of infective endocarditis (Journal of Clinical Microbiology). A significant biological feature of S. cristatus is its ability to antagonize the periodontal pathogen Porphyromonas gingivalis by signaling through the Mfa1 fimbriae, thereby inhibiting its colonization (Xie et al., 2000). Because it is a whole organism rather than a single molecular target like a receptor or enzyme, therapeutic focus is generally on its eradication using antibiotics such as penicillin or vancomycin during systemic infection (NIH).
Inhibition of bacterial cell wall synthesis or protein synthesis
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Streptococcus cristatus (S. cristatus).